The authors reply

Laura McCullagh; Lesley Tilson; Cathal Walsh; Michael Barry

doi:10.2165/11535720-000000000-00000

The authors reply

Laura McCullagh, Lesley Tilson, Cathal Walsh, Michael Barry

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	784-785
Number of pages	2
Journal	PharmacoEconomics
Volume	28
Issue number	9
DOIs	https://doi.org/10.2165/11535720-000000000-00000
Publication status	Published - 2010
Externally published	Yes

Keywords

Anticoagulants, therapeutic use
Antithrombotics, therapeutic use
Ardeparin-sodium, therapeutic use
Cost-effectiveness
Dabigatran-etexilate, therapeutic use
Dalteparin-sodium, therapeutic use
Deep-vein-thrombosis, prevention
Enoxaparin-sodium, therapeutic use
Factor-Xa-inhibitors, therapeutic use
Fondaparinux-sodium, therapeutic use
Low-molecular-weight-heparins, therapeutic use
Pulmonary-embolism, prevention
Research-and-development
Rivaroxaban, therapeutic use
Tinzaparin-sodium, therapeutic use
Warfarin, therapeutic use

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2165/11535720-000000000-00000

Cite this

@article{a3f190f7388f4f2ab4894c89535b2b4b,

title = "The authors reply",

keywords = "Anticoagulants, therapeutic use, Antithrombotics, therapeutic use, Ardeparin-sodium, therapeutic use, Cost-effectiveness, Dabigatran-etexilate, therapeutic use, Dalteparin-sodium, therapeutic use, Deep-vein-thrombosis, prevention, Enoxaparin-sodium, therapeutic use, Factor-Xa-inhibitors, therapeutic use, Fondaparinux-sodium, therapeutic use, Low-molecular-weight-heparins, therapeutic use, Pulmonary-embolism, prevention, Research-and-development, Rivaroxaban, therapeutic use, Tinzaparin-sodium, therapeutic use, Warfarin, therapeutic use",

author = "Laura McCullagh and Lesley Tilson and Cathal Walsh and Michael Barry",

year = "2010",

doi = "10.2165/11535720-000000000-00000",

language = "English",

volume = "28",

pages = "784--785",

journal = "PharmacoEconomics",

issn = "1170-7690",

number = "9",

}

TY - JOUR

T1 - The authors reply

AU - McCullagh, Laura

AU - Tilson, Lesley

AU - Walsh, Cathal

AU - Barry, Michael

PY - 2010

Y1 - 2010

KW - Anticoagulants, therapeutic use

KW - Antithrombotics, therapeutic use

KW - Ardeparin-sodium, therapeutic use

KW - Cost-effectiveness

KW - Dabigatran-etexilate, therapeutic use

KW - Dalteparin-sodium, therapeutic use

KW - Deep-vein-thrombosis, prevention

KW - Enoxaparin-sodium, therapeutic use

KW - Factor-Xa-inhibitors, therapeutic use

KW - Fondaparinux-sodium, therapeutic use

KW - Low-molecular-weight-heparins, therapeutic use

KW - Pulmonary-embolism, prevention

KW - Research-and-development

KW - Rivaroxaban, therapeutic use

KW - Tinzaparin-sodium, therapeutic use

KW - Warfarin, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=77956245660&partnerID=8YFLogxK

U2 - 10.2165/11535720-000000000-00000

DO - 10.2165/11535720-000000000-00000

M3 - Letter

AN - SCOPUS:77956245660

SN - 1170-7690

VL - 28

SP - 784

EP - 785

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 9

ER -

The authors reply

Keywords

UN SDGs

Access to Document

Other files and links

Cite this